An Investigational Study to Evaluate the Effect of Rifampin on the Singe Dose of Experimental Medication BMS-986224 in Healthy Participants

Completed · Phase 1

Conditions studied: Healthy Participants

In brief

The purpose of this study is to investigate if the blood levels of experimental medication BMS-986224 will be changed when given together with Rifampin, an antibiotic that affects specific enzymes involved with the breakdown of BMS-986224.

Key facts

Study ID

NCT03563950

Run by

Bristol-Myers Squibb

People needed

42

Starts

2018-06-01

Expected to finish

2018-07-27

Last updated by the study team

2018-08-29

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy participant, as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
• Body mass index (BMI)of 18.0to 30.0 kg/m2, inclusive, at screening

You may not qualify if…

• Women of childbearing potential
• Any significant acute or chronic medical illness
• Current or recent (within 3 months of study treatment administration) gastrointestinal disease that could affect absorption or history of cholecystectomy
• Other protocol defined inclusion/exclusion criteria may apply

Where it is running

• PRA Health Sciences — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.